A30
Conditions
Interventions
Group 1: Active case finding for new leprosy cases in the vicinity of reported cases in the last 5 years and post-exposure prophylaxis (PEP) with a single dose of rifampicin 10 mg / kg, max 600 mg for
Sponsors
Deutsche Lepra und Tuberkulosehilfe e.V.
Eligibility
Sex/Gender
All
Age
2 Years to No maximum
Inclusion criteria
Inclusion criteria: Anyone usually residing in the villages reporting leprosy cases in the last five years and are considered for active screening and aged 2 years or over regardless of their sex, social, ethnic or religious affiliation.
Exclusion criteria
Exclusion criteria: - Refusal to give informed consent for screening or for the disclosure of the diagnosis to other members of his family - Refusal to give informed consent for PEP - Age <2 years - New leprosy confirmed (cases should be put on MDT if they have not yet received MDT) or suspected, until the disease is ruled out - overt signs and / or symptoms of tuberculosis (patients with any of the following symptoms should be referred to a tuberculosis diagnostic center for screening for the following symptoms: cough for more than two weeks, night sweats, unexplained fever , weightloss) - Treatment with rifampicin for a given reason within the last two years (e.g. for treatment of tuberculosis or leprosy, or as contact with another index case) - Pregnancy (PEP can be given after childbirth) - History of liver problems (eg jaundice) or kidney problems - Allergy to rifampicin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| newly diagnosed patients during active case finding activity and in the following two years | — |
Secondary
| Measure | Time frame |
|---|---|
| Grade 2 disabilities | — |
Countries
Senegal
Contacts
Public ContactMadoky Magatte Diop
spécialiste en Médecine Interne et en Léprologie, chef du service de Médecine Interne de l’Hôpital Régional de Thiès
Outcome results
None listed